{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024980","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.478429+00:00","generated_at":"2026-06-21T19:47:54.317215+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eledon reports Q3 net loss $10.5M; advances tegoprubart with FDA IND clearances","bullets":["Net loss of $10.5M ($0.73/share) vs $9.8M ($0.66/share) in Q3 2021.","Cash and equivalents $65.9M as of Sep 30, 2022; runway into 2024.","FDA cleared IND for Phase 2 trial of tegoprubart in kidney transplant prevention.","FDA cleared IND for tegoprubart in IgA Nephropathy; global Phase 2a enrolling.","Initial data from kidney, islet cell, and IgAN studies expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024980","json":"https://secwatch.observer/filing/0000950170-22-024980.json","markdown":"https://secwatch.observer/filing/0000950170-22-024980.md","text":"https://secwatch.observer/filing/0000950170-22-024980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017022024980/0000950170-22-024980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017022024980/eldn-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:47:54.317215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8527a8520ac3e43112290f43f280cdb632a1d50f","claim":"Eledon Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: net income $10.5 million, EPS $0.73 per share.","evidence_excerpt":"The company reported a net loss of $10.5 million, or $0.73 per share, for the three months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017022024980/0000950170-22-024980-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"$10.5 million"},{"label":"EPS","value":"$0.73 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}